Gujarat Terce Laboratories has intimated BSE Limited of an upcoming Board of Directors meeting, scheduled for Wednesday, May 27, 2026. The intimation, dated May 13, 2026, was filed in compliance with Regulation 29 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Board Meeting Agenda

The Board of Directors is set to convene to deliberate on key corporate matters. The following items are on the agenda for the meeting:

• Consider and approve the Annual Audited Standalone Financial Results of the company for the fourth quarter and financial year ended March 31, 2026
• Consider matters related to the ensuing Annual General Meeting of the company

The key details of the scheduled board meeting are summarised below:

Trading Window Closure

In accordance with the company's Code of Conduct for Prevention of Insider Trading in Securities of Gujarat Terce Laboratories, the Trading Window has been closed from Wednesday, April 1, 2026 to Friday, May 29, 2026, both days inclusive, in connection with the consideration of the said financial results.

The intimation has also been uploaded on the company's website and is accessible at https://www.gujaratterce.in/financial-results/ . The filing was signed by Ashka Solanki, Company Secretary, on behalf of Gujarat Terce Laboratories.

Gujarat Terce Laboratories Limited has secured trading approval from BSE for 3,71,000 equity shares allotted through warrant conversion on preferential basis. The pharmaceutical company informed the exchange about receiving the trading approval for shares issued to promoter Mr. Aalap Prajapati.

Share Allotment Details

The trading approval covers equity shares with specific parameters as outlined by BSE:

Trading Commencement

BSE issued the trading approval through letter bearing reference number LOD/PREF/SV/394/2025-2026 dated February 24, 2026. The exchange confirmed that trading in these securities would commence effectively from Wednesday, February 25, 2026. The approval was communicated to trading members through BSE Notice No. 20260224-9 dated February 24, 2026.

Regulatory Compliance

The company made the disclosure pursuant to Regulation 30 read with Schedule III of SEBI Listing Regulations. Company Secretary Ms. Ashka Solanki signed the intimation letter, ensuring compliance with regulatory requirements for informing stakeholders about the trading approval.

Financial Impact

The warrant conversion represents a significant capital infusion for the company:

The preferential allotment to the promoter strengthens the company's equity base while maintaining promoter participation in the business growth.